I-Mab (IMAB) Stock Price, News, Quote & History - Yahoo Finance (2024)

0&&s)if(o){var r,a=(r=e.newCount)>99;s.textContent=a?"99+":r+"",null===(t=s.parentElement)||void 0===t||t.classList.add(Wt)}else s.style.display="block"},f=function(){d.refreshPanel().then(m).then(ee).catch((function(){}))};e.addEventListener("close-all-menus",(function(){xe(c)||u()})),c&&(f(),setInterval((function(){f()}),3e5),o?l&&l.addEventListener("mouseenter",(function(){p(),null==t||t.show()})):c.addEventListener("mouseenter",(function(){p(),null==t||t.show()})),c.addEventListener("mouseleave",(function(){u(),null==t||t.hide()}))),e.addElementListener(i,"click",(function(){Q("ybar","notification","",{elm:"btn",elmt:"block"===(null==s?void 0:s.style.display)?"newalert":"",subsec:"notification",itc:"1"})})),r&&Ee(e,r,"ybar","notification",{elm:"expand",subsec:"notifications",itc:"2"}),e.addElementListener(a,"focusin",(function(){i&&(i.checked=!0),null==a||a.classList.add("ybarMenuOpen")})),e.addElementListener(a,"focusout",u),e.addElementListener(n.tooltipContainer,"focusin",(function(){null==t||t.show()})),e.addElementListener(n.tooltipContainer,"focusout",(function(){null==t||t.hide()}));var h=e.getConfig().device,v=document.getElementById("ybar");v&&v.classList.contains("ybar-ytheme-crunch")&&(to=0);var y=new RegExp("[?&]notifications=1(&|#|$)");"desktop"===h&&i&&y.test(window.location.search)&&(i.checked=!0)};ye("ybar-mod-notification",(function(e){var n={isUH3:"crunch"===e.getConfig().ytheme,notifContainer:document.getElementById("notification-container"),notifBadge:document.getElementById("notif-badge"),notifMenu:document.getElementById("ybarNotificationMenu"),notifMenuOpener:document.querySelector("#ybarNotificationMenu + label"),notifDropdown:document.getElementById("notifDropdownContainer"),tooltipContainer:document.querySelector(".".concat(Jt)),notifLabel:document.querySelector(".".concat(Vt))};io(e,n)}))}()}};

NasdaqGM - Delayed Quote USD

Compare

1.1500 +0.0400 (+3.60%)

At close: September 27 at 4:00 PM EDT

1.1570 +0.01 (+0.61%)

After hours: September 27 at 4:53 PM EDT

Line

Candle

Baseline

Mountain

Bar

Advanced Chart

Loading Chart for IMAB

9/21 12:03 PM

DELL

Date
Close
Open
High
Low
Volume
  • Previous Close 1.1100
  • Open 1.1500
  • Bid 0.8136 x 200
  • Ask 1.3900 x 200
  • Day's Range 1.0800 - 1.1596
  • 52 Week Range 0.9900 - 2.5360
  • Volume 416,135
  • Avg. Volume 239,631
  • Market Cap (intraday) 89.213M
  • Beta (5Y Monthly) 1.07
  • PE Ratio (TTM) --
  • EPS (TTM) -2.2600
  • Earnings Date Aug 28, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 6.75

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

ir.i-mabbiopharma.com

34

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

More about I-Mab

Recent News: IMAB

View More

All SEC Filings

Corporate Changes & Voting Matters

Periodic Financial Reports

Proxy Statements

Tender Offer/Acquisition Reports

Offering Registrations

View More

Performance Overview: IMAB

Trailing total returns as of 9/28/2024, which may include dividends or other distributions. Benchmark is

MSCI WORLD

.

YTD Return

IMAB

39.47%

MSCI WORLD

17.59%

1-Year Return

IMAB

6.50%

MSCI WORLD

31.19%

3-Year Return

IMAB

98.36%

MSCI WORLD

20.39%

5-Year Return

IMAB

92.20%

MSCI WORLD

54.29%

Compare To: IMAB

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

IMABI-Mab

1.1500

+3.60%

Mkt Cap 89.213M

Industry Biotechnology

ZLABZai Lab Limited

23.63

+4.56%

Mkt Cap 2.354B

Industry Biotechnology

SYRSSyros Pharmaceuticals, Inc.

2.0000

+2.04%

Mkt Cap 53.62M

Industry Biotechnology

BGNEBeiGene, Ltd.

218.42

+2.77%

Mkt Cap 24.376B

Industry Biotechnology

CCCCC4 Therapeutics, Inc.

5.89

-5.46%

Mkt Cap 408.4M

Industry Biotechnology

IOBTIO Biotech, Inc.

1.0600

-0.93%

Mkt Cap 69.834M

Industry Biotechnology

LEGNLegend Biotech Corporation

49.27

+5.17%

Mkt Cap 9.08B

Industry Biotechnology

IGMSIGM Biosciences, Inc.

17.00

+7.19%

Mkt Cap 1.008B

Industry Biotechnology

CABACabaletta Bio, Inc.

4.2600

+6.77%

Mkt Cap 208.095M

Industry Biotechnology

MRSNMersana Therapeutics, Inc.

1.8500

0.00%

Mkt Cap 226.949M

Industry Biotechnology

VTYXVentyx Biosciences, Inc.

2.3100

-2.12%

Mkt Cap 163.246M

Industry Biotechnology

Statistics: IMAB

View More

Valuation Measures

Annual

As of 9/27/2024

  • Market Cap

    89.21M

  • Enterprise Value

    -114.31M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    26.31

  • Price/Book (mrq)

    0.38

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -29.25%

  • Return on Equity (ttm)

    -71.72%

  • Revenue (ttm)

    3.49M

  • Net Income Avi to Common (ttm)

    -205.6M

  • Diluted EPS (ttm)

    -2.2600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    207.49M

  • Total Debt/Equity (mrq)

    1.67%

  • Levered Free Cash Flow (ttm)

    --

View More

Research Analysis: IMAB

View More
View More

Company Insights: IMAB

Research Reports: IMAB

View More
View More

People Also Watch

ZLAB Zai Lab Limited

23.63

+4.56%

LEGN Legend Biotech Corporation

49.27

+5.17%

ALXO ALX Oncology Holdings Inc.

1.9700

+5.35%

BNR Burning Rock Biotech Limited

3.2500

-1.81%

IGMS IGM Biosciences, Inc.

17.00

+7.19%

ZNTL Zentalis Pharmaceuticals, Inc.

3.7500

+1.63%

KROS Keros Therapeutics, Inc.

56.45

-0.76%

KYMR Kymera Therapeutics, Inc.

48.69

-1.58%

GBIO Generation Bio Co.

2.4300

+4.74%

BGNE BeiGene, Ltd.

218.42

+2.77%

RLAY Relay Therapeutics, Inc.

7.46

+0.81%

ITOS iTeos Therapeutics, Inc.

10.50

+3.30%

BDTX Black Diamond Therapeutics, Inc.

4.2300

-4.08%

RVMD Revolution Medicines, Inc.

44.17

+0.71%

INBX Inhibrx Biosciences, Inc.

15.52

+1.24%

BCYC Bicycle Therapeutics plc

23.21

-0.47%

I-Mab (IMAB) Stock Price, News, Quote & History - Yahoo Finance (2024)
Top Articles
Latest Posts
Recommended Articles
Article information

Author: Aron Pacocha

Last Updated:

Views: 6491

Rating: 4.8 / 5 (48 voted)

Reviews: 87% of readers found this page helpful

Author information

Name: Aron Pacocha

Birthday: 1999-08-12

Address: 3808 Moen Corner, Gorczanyport, FL 67364-2074

Phone: +393457723392

Job: Retail Consultant

Hobby: Jewelry making, Cooking, Gaming, Reading, Juggling, Cabaret, Origami

Introduction: My name is Aron Pacocha, I am a happy, tasty, innocent, proud, talented, courageous, magnificent person who loves writing and wants to share my knowledge and understanding with you.